Loading...
Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males
CONTEXT: TAK-385 is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment. OBJECTIVE: The objectives were to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-385 on LH and testosterone. DESIGN, SETTING, AND PARTICI...
Na minha lista:
| Udgivet i: | J Clin Endocrinol Metab |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Endocrine Society
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4667159/ https://ncbi.nlm.nih.gov/pubmed/26502357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-2770 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|